Product Description
Calcitonin is a hormone that the C-cells in the thyroid gland produce and release. It opposes the action of the parathyroid hormone, helping to regulate the bloods calcium and phosphate levels.
Mechanisms of Action: Calcitonin Receptor Stimulant
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nordic Bioscience
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Generalized anxiety disorder
Phase 3: Osteoarthritis, Knee|Osteoporosis|Osteoporosis, Postmenopausal|Osteoarthritis
Phase 2: Osteoporosis, Postmenopausal|Bone Diseases, Metabolic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2006-7041-83/hah | P4 |
Withdrawn |
Generalized anxiety disorder |
2019-08-31 |
|||
| TAR-01-201 | P2 |
Completed |
Bone Diseases, Metabolic|Osteoporosis, Postmenopausal |
2012-05-01 |
2025-02-07 |
Primary Endpoints|Treatments |
|
| SMC021A2303 | P3 |
Completed |
Osteoporosis |
2011-08-01 |
2025-02-07 |
Primary Endpoints |
|
| 2007-003016-60 | P3 |
Completed |
Osteoarthritis |
2011-04-30 |
2022-03-12 |
Treatments |
|
| ORACAL | P3 |
Completed |
Osteoporosis, Postmenopausal |
2011-02-01 |
2025-02-07 |
||
| CSMC021C2301 | P3 |
Completed |
Osteoarthritis, Knee |
2010-09-01 |
2025-02-07 |
Primary Endpoints |
|
| 2005-004145-34 | P3 |
Completed |
Osteoarthritis, Knee |
2008-10-13 |
2025-05-23 |
Treatments |